Skip to main content
. 2020 Nov 27;6(48):eabc8733. doi: 10.1126/sciadv.abc8733

Fig. 7. Evaluation of combination therapy effect.

Fig. 7

(A) Schematic illustration of Ag2S@Fe2C-DSPE-PEG-iRGD nanocapsule-based tumor therapy. (B) Real-time thermal infrared images of 4T1 breast cancer–bearing mice after intravenous injection of saline, Ag2S@Fe2C-DSPE-PEG + laser, Ag2S@Fe2C-DSPE-PEG + laser + bevacizumab, Ag2S@Fe2C-DSPE-PEG-iRGD + laser, and Ag2S@Fe2C-DSPE-PEG-iRGD + laser + bevacizumab under 808-nm laser irradiation (0.3 W cm−2, 5 min). (C) Representative photograph for volume change of tumor in the different treatments in 30 days. Photo credit: Zhiyi Wang, Peking University, China. (D) Volume change of tumor in the different treatments. (E) H&E-stained images of tumor regions with different treatments. Error bars, means ± SD (n = 5), unpaired t test.